Chiesi, USA (Formerly Known As Cornerstone Therapeutics)

128 articles about Chiesi, USA (Formerly Known As Cornerstone Therapeutics)

• Chiesi USA Appoints Richard Smith as Vice President and Business Unit Leader, U.S. AIR

  4/15/2024

  Chiesi USA, Inc. today announced it has appointed Richard Smith as vice president and business unit leader of U.S. AIR.

• Chiesi Global Rare Diseases Announces Multiple Presentations at SSIEM Annual Symposium 2023

  9/1/2023

  Chiesi Global Rare Diseases, a business unit of the Chiesi Group established to deliver innovative therapies and solutions for people affected by rare diseases, announced multiple presentations at the Society for the Study of Inborn Errors of Metabolism Annual Symposium 2023 being held August 29 - September 1, 2023, in Jerusalem, Israel.

• Chiesi Global Rare Diseases Announces Co-Development Agreement with Aliada Therapeutics to Advance Blood-Brain Barrier-Crossing Platform Technology in Lysosomal Storage Disorders

  8/15/2023

  Chiesi Global Rare Diseases, a business unit of the Chiesi Group established to deliver innovative therapies and solutions for people living with rare diseases, announced a co-development agreement with Aliada Therapeutics, a biotechnology company developing a novel blood-brain barrier -crossing platform technology to address challenging disease areas with high unmet need.

• Chiesi Group Mid-Year Financial Results Demonstrate Strong Growth for 2023

  8/8/2023

  Chiesi USA, Inc., a Cary-based specialty pharmaceutical company, announced that Chiesi Group is continuing to experience major growth this year.

• Chiesi USA CEO Appointed to ASHP Foundation Board of Directors

  7/20/2023

  Chiesi USA, Inc., a Cary-based specialty pharmaceutical company, announced that Jon Zwinski, CEO and General Manager at Chiesi USA, has been appointed to the American Society of Health-System Pharmacists Foundation Board of Directors.

• Chiesi USA Partners with Smith Anderson to Host 1L Excellence in Diversity Fellow this Summer

  6/12/2023

  Chiesi USA, Inc., a Cary-based specialty pharmaceutical company, in partnership with Smith Anderson, a Triangle-based full-service business and litigation law firm, will host Cecilia Poston, the firm’s 2023 1L Excellence in Diversity Fellow for three weeks this month.

• Chiesi USA Sponsors ASHP Advantage Initiative to Support Pharmacy Technician Recruitment and Retention

  12/2/2022

  Chiesi USA, the U.S. affiliate of Chiesi Farmaceutici, an international research-focused healthcare group, announced its sponsorship of the ASHP Advantage initiative to support pharmacy technician recruitment and retention.

• Chiesi USA Announces Publication of Health Economics Analysis of Selective Early Rescue Surfactant Administration vs. Standard Surfactant Administration for Premature Infants with Respiratory Distress Syndrome

  11/29/2022

  Chiesi USA, the U.S. affiliate of Chiesi Farmaceutici, an international research-focused healthcare group, announced the publication of an article describing a health economic model comparing selective early rescue surfactant administration versus standard surfactant administration for infants with respiratory distress syndrome.

• Chiesi USA Chosen as One of Fortune’s 25 Best Small and Medium Workplaces in Biotechnology and Pharmaceuticals

  10/17/2022

  Chiesi USA, Inc., the U.S. affiliate of Chiesi Farmaceutici S.p.A., an international research-focused healthcare Group, has been ranked No. 15 among Fortune’s 25 Best Small and Medium Workplaces in Biotechnology and Pharmaceuticals.

• Chiesi tracks actions taken for a healthier, more sustainable future

  7/14/2022

  Chiesi, the international research-focused biopharmaceutical group, released its Annual and Sustainability Report for 2021.

• Chiesi USA certified as a Great Place to Work® in 2021

  2/24/2022

  Chiesi USA, Inc., a Cary-based specialty pharmaceutical company, has earned the Great Place to Work® Certification for 2021 in the U.S., following its first recognition in 2019.

• A new clinical framework redefines the diagnosis of COPD Exacerbations

  12/20/2021

  Chiesi USA, the U.S. affiliate of Chiesi Farmaceutici, the international research-focused pharmaceuticals and healthcare Group, welcomes the findings of an international panel of expert clinicians gathered to re-define the clinical pathways for diagnosing and classifying exacerbations of chronic obstructive pulmonary disease at the 2021 International Meeting on Asthma and COPD hosted in Florence, Italy.

• Chiesi accelerates path toward full sustainability despite COVID-19 pandemic

  6/23/2021

  Chiesi USA, the U.S. affiliate of Chiesi Farmaceutici, an international research-focused healthcare Group, further accelerated its path toward becoming a fully sustainable company, despite an extremely challenging 2020, which was overshadowed by the COVID-19 pandemic.

• Chiesi USA announces new organizational leadership for the Chiesi Foundation

  5/13/2021

  Chiesi USA, the U.S. affiliate of Chiesi Farmaceutici, an international research-focused healthcare Group, announced that Maria Paola Chiesi was appointed President of the Chiesi Foundation, a non-profit organization established in 2005 as an expression of the corporate social responsibility of the Chiesi Group.

• Chiesi Group calls for #ActionOverWords in the fight against climate change

  5/10/2021

  Chiesi Group, the largest international pharmaceutical company Certified B Corporation™, reinforces 2035 carbon neutral target with #ActionOverWords campaign to encourage measurable sustainability commitments and invite accountability.

• Chiesi USA Appoints VP of Medical Affairs to Support Continued GrowthMartin Marciniak, RPh, MPP, PhD, appointed as Vice President of Medical Affairs

  3/29/2021

  Chiesi USA, the U.S. affiliate of Chiesi Farmaceutici S.p.A., an international research-focused healthcare Group, has appointed Martin Marciniak, RPh, MPP, PhD, as Vice President of Medical Affairs to progress the company’s therapeutic area efforts.

• Chiesi continues cultural transformation with new visual identity that mirrors patients’ language and experiences

  3/22/2021

  New visual identity is the first public manifestation of Chiesi Group’s continued transformation as a Certified B Corporation™ business

• Chiesi Group announces performance growth in 2020

  3/18/2021

  These results are confirmation of significant growth in 2020 for Chiesi, which has been a Benefit Company since 2018 and Certified B Corporation™ since 2019.

• Chiesi USA, Inc. announces Commercial Availability of Bronchitol® (mannitol) inhalation powder for improvement in pulmonary function in adult patients with cystic fibrosisPhase 3 clinical trial data published in the Journal of Cystic Fibrosis

  3/17/2021

  Chiesi USA, Inc. , the U.S. affiliate of Chiesi Farmaceutici, an international research-focused healthcare Group (Chiesi Group), today announced the launch of FDA-approved Bronchitol® (mannitol) inhalation powder, an add-on maintenance therapy to improve pulmonary function in cystic fibrosis (CF) patients 18 years of age and older.

• Chiesi USA Announces Sponsorship of ASHP Foundation’s Pharmacy Leadership Scholars ProgramProgram advances research in diversity, equity and inclusion in healthcare

  3/16/2021

  Chiesi USA, the U.S. affiliate of Chiesi Farmaceutici S.p.A., an international research-focused healthcare Group, announced its sponsorship of the ASHP Foundation Pharmacy Leadership Scholars™ program for early-stage pharmacist researchers.